{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:52:34Z","timestamp":1792896754110,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1185907"],"award-info":[{"award-number":["1185907"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1164020"],"award-info":[{"award-number":["1164020"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1068510"],"award-info":[{"award-number":["1068510"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001043","name":"Cass Foundation","doi-asserted-by":"publisher","award":["SM12\/4249"],"award-info":[{"award-number":["SM12\/4249"]}],"id":[{"id":"10.13039\/501100001043","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite significant therapeutic advances, lung cancer remains the leading cause of cancer-related death worldwide<jats:sup>1<\/jats:sup>. Non-small cell lung cancer (NSCLC) patients have a very poor overall five-year survival rate of only 10\u201320%. Currently, TNM staging is the gold standard for predicting overall survival and selecting optimal initial treatment options for NSCLC patients, including those with curable stages of disease. However, many patients with locoregionally-confined NSCLC relapse and die despite curative-intent interventions, indicating a need for intensified, individualised therapies. Epithelial-to-mesenchymal transition (EMT), the phenotypic depolarisation of epithelial cells to elongated, mesenchymal cells, is associated with metastatic and treatment-refractive cancer. We demonstrate here that EMT-induced protein changes in small extracellular vesicles are detectable in NSCLC patients and have prognostic significance. Overall, this work describes a novel prognostic biomarker signature that identifies potentially-curable NSCLC patients at risk of developing metastatic NSCLC, thereby enabling implementation of personalised treatment decisions.<\/jats:p>","DOI":"10.1038\/s42003-022-04350-4","type":"journal-article","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T12:03:04Z","timestamp":1674043384000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["An epithelial-to-mesenchymal transition induced extracellular vesicle prognostic signature in non-small cell lung cancer"],"prefix":"10.1038","volume":"6","author":[{"given":"Richard J.","family":"Lobb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8393-4209","authenticated-orcid":false,"given":"Kekoolani S.","family":"Visan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1509-9440","authenticated-orcid":false,"given":"Li-Ying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma L.","family":"Norris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus L.","family":"Hastie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Everitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian A.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayleen V.","family":"Bowman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar","family":"Siva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill E.","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey J.","family":"Gorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"MacManus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Leimgruber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwun M.","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8618-6998","authenticated-orcid":false,"given":"Andreas","family":"M\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,18]]},"reference":[{"key":"4350_CR1","first-page":"87","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre, L. A. et al. Global cancer statistics, 2012. CA: Cancer J. Clin. 65, 87\u2013108 (2015).","journal-title":"CA: Cancer J. Clin."},{"key":"4350_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"4350_CR3","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/S0025-6196(11)60735-0","volume":"83","author":"JR Molina","year":"2008","unstructured":"Molina, J. R., Yang, P., Cassivi, S. D., Schild, S. E. & Adjei, A. A. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin. Proc. 83, 584\u2013594 (2008).","journal-title":"Mayo Clin. Proc."},{"key":"4350_CR4","doi-asserted-by":"publisher","first-page":"585284","DOI":"10.3389\/fonc.2020.585284","volume":"10","author":"T Zhu","year":"2020","unstructured":"Zhu, T. et al. Mechanisms and future of non-small cell lung cancer metastasis. Front Oncol. 10, 585284 (2020).","journal-title":"Front Oncol."},{"key":"4350_CR5","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s10555-007-9055-1","volume":"26","author":"P Vaupel","year":"2007","unstructured":"Vaupel, P. & Mayer, A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 26, 225\u2013239 (2007).","journal-title":"Cancer Metastasis Rev."},{"key":"4350_CR6","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1172\/JCI39104","volume":"119","author":"R Kalluri","year":"2009","unstructured":"Kalluri, R. & Weinberg, R. A. The basics of epithelial-mesenchymal transition. J. Clin. Investig. 119, 1420\u20131428 (2009).","journal-title":"J. Clin. Investig."},{"key":"4350_CR7","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41580-020-0237-9","volume":"21","author":"J Yang","year":"2020","unstructured":"Yang, J. et al. Guidelines and definitions for research on epithelial-mesenchymal transition. Nat. Rev. Mol. Cell Biol. 21, 341\u2013352 (2020).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"4350_CR8","doi-asserted-by":"publisher","first-page":"3630","DOI":"10.1158\/1078-0432.CCR-15-1434","volume":"22","author":"Y Lou","year":"2016","unstructured":"Lou, Y. et al. Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma. Clin. Cancer Res. 22, 3630\u20133642 (2016).","journal-title":"Clin. Cancer Res."},{"key":"4350_CR9","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/nature15748","volume":"527","author":"KR Fischer","year":"2015","unstructured":"Fischer, K. R. et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 527, 472\u2013476 (2015).","journal-title":"Nature"},{"key":"4350_CR10","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41568-020-00299-w","volume":"20","author":"A Moller","year":"2020","unstructured":"Moller, A. & Lobb, R. J. The evolving translational potential of small extracellular vesicles in cancer. Nat. Rev. Cancer 20, 697\u2013709 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"4350_CR11","doi-asserted-by":"crossref","unstructured":"Kalluri, R. & LeBleu V. S. The biology, function, and biomedical applications of exosomes. Science 367, eaau6977 (2020).","DOI":"10.1126\/science.aau6977"},{"key":"4350_CR12","doi-asserted-by":"crossref","unstructured":"Lobb, R. J., Lima, L. G. & Moller A. Exosomes: Key mediators of metastasis and pre-metastatic niche formation. Seminars Cell Dev. Biol. 67, 3\u201310 (2017).","DOI":"10.1016\/j.semcdb.2017.01.004"},{"key":"4350_CR13","doi-asserted-by":"publisher","first-page":"e1800180","DOI":"10.1002\/pmic.201800180","volume":"19","author":"SW Wen","year":"2019","unstructured":"Wen, S. W. et al. Breast cancer-derived exosomes reflect the cell-of-origin phenotype. Proteomics 19, e1800180 (2019).","journal-title":"Proteomics"},{"key":"4350_CR14","first-page":"306","volume":"27","author":"Y Qin","year":"2017","unstructured":"Qin, Y. et al. MeCP2 regulated glycogenes contribute to proliferation and apoptosis of gastric cancer cells. Glycobiology 27, 306\u2013317 (2017).","journal-title":"Glycobiology"},{"key":"4350_CR15","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s13277-012-0631-9","volume":"34","author":"J Peng","year":"2013","unstructured":"Peng, J. et al. VCP gene variation predicts outcome of advanced non-small-cell lung cancer platinum-based chemotherapy. Tumour Biol. 34, 953\u2013961 (2013).","journal-title":"Tumour Biol."},{"key":"4350_CR16","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.athoracsur.2004.04.029","volume":"78","author":"CE Denlinger","year":"2004","unstructured":"Denlinger, C. E., Rundall, B. K., Keller, M. D. & Jones, D. R. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis. Ann. Thorac. Surg. 78, 1207\u20131214 (2004).","journal-title":"Ann. Thorac. Surg."},{"key":"4350_CR17","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1093\/nar\/gkv024","volume":"43","author":"YA Tang","year":"2015","unstructured":"Tang, Y. A. et al. Global Oct4 target gene analysis reveals novel downstream PTEN and TNC genes required for drug-resistance and metastasis in lung cancer. Nucleic Acids Res. 43, 1593\u20131608 (2015).","journal-title":"Nucleic Acids Res."},{"key":"4350_CR18","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/nm.2379","volume":"17","author":"T Oskarsson","year":"2011","unstructured":"Oskarsson, T. et al. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat. Med. 17, 867\u2013874 (2011).","journal-title":"Nat. Med."},{"key":"4350_CR19","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ccr.2009.01.023","volume":"15","author":"C Kudo-Saito","year":"2009","unstructured":"Kudo-Saito, C., Shirako, H., Takeuchi, T. & Kawakami, Y. Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell 15, 195\u2013206 (2009).","journal-title":"Cancer Cell"},{"key":"4350_CR20","first-page":"2535","volume":"62","author":"A Marchetti","year":"2002","unstructured":"Marchetti, A. et al. Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients. Cancer Res. 62, 2535\u20132539 (2002).","journal-title":"Cancer Res."},{"key":"4350_CR21","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1093\/jnci\/93.4.266","volume":"93","author":"M Hockel","year":"2001","unstructured":"Hockel, M. & Vaupel, P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J. Natl Cancer Inst. 93, 266\u2013276 (2001).","journal-title":"J. Natl Cancer Inst."},{"key":"4350_CR22","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.cell.2013.09.041","volume":"155","author":"HS Kim","year":"2013","unstructured":"Kim, H. S. et al. Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer. Cell 155, 552\u2013566 (2013).","journal-title":"Cell"},{"key":"4350_CR23","first-page":"26","volume":"1","author":"LR Pilz","year":"2012","unstructured":"Pilz, L. R., Manegold, C. & Schmid-Bindert, G. Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? Transl. Lung Cancer Res. 1, 26\u201335 (2012).","journal-title":"Transl. Lung Cancer Res."},{"key":"4350_CR24","doi-asserted-by":"publisher","unstructured":"Lobb R. J. et al. Oncogenic transformation of lung cells results in distinct exosome protein profile similar to the cell of origin. Proteomics https:\/\/doi.org\/10.1002\/pmic.201600432 (2017).","DOI":"10.1002\/pmic.201600432"},{"key":"4350_CR25","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.cell.2009.11.007","volume":"139","author":"JP Thiery","year":"2009","unstructured":"Thiery, J. P., Acloque, H., Huang, R. Y. & Nieto, M. A. Epithelial-mesenchymal transitions in development and disease. Cell 139, 871\u2013890 (2009).","journal-title":"Cell"},{"key":"4350_CR26","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1002\/ijc.30752","volume":"141","author":"RJ Lobb","year":"2017","unstructured":"Lobb, R. J. et al. Exosomes derived from mesenchymal non-small cell lung cancer cells promote chemoresistance. Int J. Cancer 141, 614\u2013620 (2017).","journal-title":"Int J. Cancer"},{"key":"4350_CR27","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41556-018-0196-y","volume":"21","author":"MP Stemmler","year":"2019","unstructured":"Stemmler, M. P., Eccles, R. L., Brabletz, S. & Brabletz, T. Non-redundant functions of EMT transcription factors. Nat. Cell Biol. 21, 102\u2013112 (2019).","journal-title":"Nat. Cell Biol."},{"key":"4350_CR28","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/nrc3265","volume":"12","author":"T Brabletz","year":"2012","unstructured":"Brabletz, T. To differentiate or not-routes towards metastasis. Nat. Rev. Cancer 12, 425\u2013436 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"4350_CR29","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.cell.2006.11.001","volume":"127","author":"GP Gupta","year":"2006","unstructured":"Gupta, G. P. & Massague, J. Cancer metastasis: building a framework. Cell 127, 679\u2013695 (2006).","journal-title":"Cell"},{"key":"4350_CR30","doi-asserted-by":"crossref","unstructured":"Salem A. et al. Targeting hypoxia to improve non-small cell lung cancer outcome. J. Natl Cancer Inst. 110, 14\u201330 (2018).","DOI":"10.1093\/jnci\/djx160"},{"key":"4350_CR31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1158\/2326-6066.CIR-16-0103","volume":"5","author":"NE Scharping","year":"2017","unstructured":"Scharping, N. E., Menk, A. V., Whetstone, R. D., Zeng, X. & Delgoffe, G. M. Efficacy of PD-1 blockade is potentiated by metformin-induced reduction of tumor hypoxia. Cancer Immunol. Res 5, 9\u201316 (2017).","journal-title":"Cancer Immunol. Res"},{"key":"4350_CR32","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1159\/000515289","volume":"211","author":"MK Jolly","year":"2022","unstructured":"Jolly, M. K. et al. Measuring and modelling the epithelial- mesenchymal hybrid state in cancer: clinical implications. Cells Tissues Organs 211, 110\u2013133 (2022).","journal-title":"Cells Tissues Organs"},{"key":"4350_CR33","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nature16064","volume":"527","author":"X Zheng","year":"2015","unstructured":"Zheng, X. et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 527, 525\u2013530 (2015).","journal-title":"Nature"},{"key":"4350_CR34","first-page":"154","volume":"2","author":"D Xiao","year":"2010","unstructured":"Xiao, D. & He, J. Epithelial mesenchymal transition and lung cancer. J. Thorac. Dis. 2, 154\u2013159 (2010).","journal-title":"J. Thorac. Dis."},{"key":"4350_CR35","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1172\/JCI76725","volume":"126","author":"JE Larsen","year":"2016","unstructured":"Larsen, J. E. et al. ZEB1 drives epithelial-to-mesenchymal transition in lung cancer. J. Clin. Investig. 126, 3219\u20133235 (2016).","journal-title":"J. Clin. Investig."},{"key":"4350_CR36","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.jprot.2009.07.001","volume":"73","author":"GL Hortin","year":"2010","unstructured":"Hortin, G. L. & Sviridov, D. The dynamic range problem in the analysis of the plasma proteome. J. Proteom. 73, 629\u2013636 (2010).","journal-title":"J. Proteom."},{"key":"4350_CR37","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nature15756","volume":"527","author":"A Hoshino","year":"2015","unstructured":"Hoshino, A. et al. Tumour exosome integrins determine organotropic metastasis. Nature 527, 329\u2013335 (2015).","journal-title":"Nature"},{"key":"4350_CR38","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/nature14581","volume":"523","author":"SA Melo","year":"2015","unstructured":"Melo, S. A. et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature 523, 177\u2013182 (2015).","journal-title":"Nature"},{"key":"4350_CR39","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.cell.2020.07.009","volume":"182","author":"A Hoshino","year":"2020","unstructured":"Hoshino, A. et al. Extracellular vesicle and particle biomarkers define multiple human cancers. Cell 182, 1044\u20131061.e1018 (2020).","journal-title":"Cell"},{"key":"4350_CR40","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1158\/0008-5472.CAN-05-2521","volume":"66","author":"M Sato","year":"2006","unstructured":"Sato, M. et al. Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res. 66, 2116\u20132128 (2006).","journal-title":"Cancer Res."},{"key":"4350_CR41","doi-asserted-by":"publisher","first-page":"27031","DOI":"10.3402\/jev.v4.27031","volume":"4","author":"RJ Lobb","year":"2015","unstructured":"Lobb, R. J. et al. Optimized exosome isolation protocol for cell culture supernatant and human plasma. J. Extracell. Vesicles 4, 27031 (2015).","journal-title":"J. Extracell. Vesicles"},{"key":"4350_CR42","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/978-1-4939-7253-1_9","volume":"1660","author":"R Lobb","year":"2017","unstructured":"Lobb, R. & Moller, A. Size exclusion chromatography: a simple and reliable method for exosome purification. Methods Mol. Biol. 1660, 105\u2013110 (2017).","journal-title":"Methods Mol. Biol."},{"key":"4350_CR43","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/nbt.1511","volume":"26","author":"J Cox","year":"2008","unstructured":"Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367\u20131372 (2008).","journal-title":"Nat. Biotechnol."},{"key":"4350_CR44","doi-asserted-by":"publisher","unstructured":"Lobb R. J. et al. Oncogenic transformation of lung cells results in distinct exosome protein profile similar to the cell of origin. Proteomics https:\/\/doi.org\/10.1002\/pmic.201600432 (2017).","DOI":"10.1002\/pmic.201600432"},{"key":"4350_CR45","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.ijrobp.2017.07.035","volume":"99","author":"S Everitt","year":"2017","unstructured":"Everitt, S. et al. Prospective study of serial imaging comparing fluorodeoxyglucose Positron Emission Tomography (PET) and fluorothymidine PET during radical chemoradiation for non-small cell lung cancer: reduction of detectable proliferation associated with worse survival. Int J. Radiat. Oncol. Biol. Phys. 99, 947\u2013955 (2017).","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"key":"4350_CR46","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.2967\/jnumed.113.131631","volume":"55","author":"SJ Everitt","year":"2014","unstructured":"Everitt, S. J. et al. Differential (18)F-FDG and (18)F-FLT uptake on serial PET\/CT imaging before and during definitive chemoradiation for non-small cell lung cancer. J. Nucl. Med. 55, 1069\u20131074 (2014).","journal-title":"J. Nucl. Med."},{"key":"4350_CR47","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4350_CR48","doi-asserted-by":"publisher","first-page":"D543","DOI":"10.1093\/nar\/gkab1038","volume":"50","author":"Y Perez-Riverol","year":"2022","unstructured":"Perez-Riverol, Y. et al. The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences. Nucleic Acids Res. 50, D543\u2013D552 (2022).","journal-title":"Nucleic Acids Res."}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-022-04350-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-022-04350-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-022-04350-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T13:14:38Z","timestamp":1674047678000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-022-04350-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,18]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4350"],"URL":"https:\/\/doi.org\/10.1038\/s42003-022-04350-4","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,18]]},"assertion":[{"value":"31 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"QIMR has filed a patent application (PCT\/AU2017\/051298) based on the findings presented in this publication with R.J.L., A.L. and A.M. as co-inventors. A.L. is co-founder of Biopsomic (Switzerland). The authors declare no other competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"68"}}